BUSINESS

Shionogi Chief Defends Xocova Data, Eager to Prove Benefits in Clinical Settings

By Takashi Ebisawa November 25, 2022

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Shionogi President Isao Teshirogi on November 24 expressed the company’s unflinching confidence about data obtained from its newly approved COVID-19 pill Xocova (ensitrelvir), brushing aside skepticism around what some see as marginal benefits offered by the medicine. “Of the three…

To read the full story

Japan Govt to Purchase Another 1 Million Courses of Xocova
December 14, 2022
Japan Should Hone Emergency Approval Scheme Based on Xocova Example
November 28, 2022
Japan Grants 1st Emergency Approval to Shionogi COVID Pill Xocova
November 24, 2022
Citizen’s Group Renews Opposition to Emergency Approval of Shionogi COVID-19 Pill
November 22, 2022
Shionogi’s COVID Pill Up for 3rd Round of Discussion for Emergency Approval on Nov. 22
November 15, 2022
Shionogi’s COVID Pill Hits Main Goal in PIII, Discussion on Regulatory Path to Follow
September 29, 2022
Shionogi Eyes PIII Topline Readout for COVID Pill in Aug-Sept., Sticks to H1 Approval Plan
August 2, 2022
Govt Should Examine Challenges with Emergency Approval Scheme Exposed by Shionogi Pill Review
July 25, 2022
Japan to Boost Measures to Ensure COVID Drug Access, Govt Says after Shionogi Antiviral Delay
July 22, 2022
Komeito Lawmakers Call for Assessing Shionogi’s Pill for Circulating Strains
July 22, 2022
Shionogi to Steadily Promote PIII Trial for COVID Pill after Approval Setback
July 22, 2022
Shionogi’s COVID-19 Pill Up for Expert Redeliberation on July 20
July 14, 2022
Japan Shelves Decision on Shionogi’s COVID Pill with Experts at Odds, Another Session Likely Next Month
June 23, 2022
Health Minister Defends Govt Purchase Pact for Shionogi’s COVID Pill
June 21, 2022
Citizen’s Group Opposes Emergency Approval for Shionogi’s COVID Pill
June 21, 2022
Shionogi’s COVID Pill Up for PAFSC Review for 1st Emergency Approval
June 16, 2022
Shionogi’s COVID-19 Pill Improves Respiratory and Feverish Symptoms
April 26, 2022
Shionogi COVID Pill Doesn’t Meet “Presumed Efficacy” Criteria: HSC Subcommittee Chair
April 13, 2022
Japan Inks Supply Deal for Shionogi’s COVID Pill for 1 Million People
March 25, 2022
Japan to Expedite Review for Shionogi’s COVID-19 Pill: PM
March 1, 2022
Shionogi Files COVID-19 Pill in Japan, Seeks Conditional Approval
February 25, 2022
Lawmakers Mixed on Use of Conditional Approval for Shionogi’s COVID-19 Pill
February 16, 2022

BUSINESS

Asahi Kasei Pharma Confident of Hitting FY2030 Group Sales Target: President
December 10, 2025
Astellas Sees Xtandi Patent Cliff a “Critical Phase,” Steps Up Board Oversight via EPM
December 10, 2025
PeptiDream Hits Milestone with Asahi Kasei Collaboration
December 10, 2025
Eisai’s Leqembi Added to China Commercial Insurance Drug List
December 10, 2025
Drug Makers, Wholesalers See No Major Disruptions after Aomori Quake
December 10, 2025

Chuikyo Debate on FY2026 Drug Pricing Reform

MHLW Floats Deducting Private-Practice Use for Re-Pricing, but Off-Cycle Cuts Possible; GLP-1 Eyed?

Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…

COMMENTARY

FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed

By Takashi Ebisawa

Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…

COLUMN

AI in HR: Navigating the Ethical Minefield

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…